A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

Conditions:   Castration-resistant Prostate Cancer;   Non-small Cell Lung Cancer;   Colorectal Cancer Interventions:   Drug: SM08502;   Drug: Abiraterone;   Drug: Prednisone;   Drug: Docetaxel;   Drug: FOLFIRI Protocol;   Drug: Panitumumab Sponsor:   Biosplice Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

ConclusionThe results of this systematic review and meta-analysis indicated that BMI ≥ 25 kg/m2 was a significant predictor of ARD and that hypofractionation was consistently protective. Depending on country of study, study design, and toxicity scale used, breast volume, smoking habit, diabetes, and sequential boost and bolus use were also predictive of ARD.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Clin Oral Investig. 2021 Nov 23. doi: 10.1007/s00784-021-04261-4. Online ahead of print.ABSTRACTOBJECTIVES: While risk factors of bisphosphonate (BP) associated osteonecrosis of the jaw have been properly analyzed, studies focusing on risk factors associated with denosumab (DNO) are sparse. The purpose of this study was to identify risk factors influencing the onset of medication-related osteonecrosis of the jaw (MRONJ) in patients receiving antiresorptive treatment (ART) with DNO by comparing patients suffering from MRONJ and patients without MRONJ. Multiple variables were evaluated including the impact of a previous BP i...
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
Biomed Pharmacother. 2021 Nov 18;145:112400. doi: 10.1016/j.biopha.2021.112400. Online ahead of print.ABSTRACTResistance to chemotherapy and hormonal therapy is a major clinical problem in breast cancer medicine, especially for cancer metastasis and recurrence. Di(2-ethylhexyl)phthalate (DEHP) affects drug resistance by an unknown mechanism of action. Here we analyzed breast cancer patients (N = 457) and found that Σ4MEHP (the sum of MEHP, MEHHP, MECPP and MEOHP concentrations) in urine was significantly higher (P = 0.018) in the recurrent breast cancer group compared with non-recurrent patients. Σ4MEHP-High wa...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Source Type: research
CONCLUSION: The delivery of PMRT has increased over time in women presenting with clinically node positive breast cancer who convert to ypN0 after NAC. While we identified multiple independent socioeconomic and clinical predictors of both PMRT utilization and survival, PMRT itself was not significantly associated with survival.PMID:34773699 | DOI:10.3906/sag-2109-200
Source: Turkish Journal of Medical Sciences - Category: General Medicine Authors: Source Type: research
AbstractCancer is the second leading cause of death worldwide responsible for about 10 million deaths per year. To date several approaches have been developed to treat this deadly disease including surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy, and synthetic lethality. The targeted therapy refers to targeting only specific proteins or enzymes that are dysregulated in cancer rather than killing all rapidly dividing cells, has gained much attention in the recent past. Kinase inhibition is one of the most successful approaches in targeted therapy. As of 30 March 2021, FDA has approved 65 small m...
Source: Medicinal Chemistry Research - Category: Chemistry Source Type: research
“Having cancer is terrifying. It’s scary. And going to the hospital—I really felt like a number,” says Marc Hulett, who was diagnosed with prostate cancer in 2004. Hulett had surgery to remove his prostate and has been on hormone therapy for 17 years. Every three months, he gets a blood test to monitor his progress, but he no longer feels like a number. He drives from his home in Palm Springs, Calif., to Los Angeles—which can take up to six hours—to see his oncologist, Dr. David Agus, at the Ellison Institute for Transformative Medicine. As the name suggests, the Institute isn’t ju...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Cancer healthscienceclimate Source Type: news
The objective of this study is to examine differences in presentation, treatment, and mortality between Black MBC and FBC.MethodsThe National Cancer Database was queried for all Black MBC and FBC patients, ages 18 –90, with hormone receptor-positive breast cancer diagnosed between 2010 and 2016. Hormone receptor positivity was defined as estrogen receptor-positive, progesterone-positive and HER 2-negative cancer. Sociodemographic and clinical variables were compared between MBC and FBC patients on bivariabl e analysis. After propensity score matching, overall survival was evaluated using the log-rank test and Cox pro...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
CONCLUSION: Our results support the clinical utility of the RS assay in ER+ HER2-negative BC with 1 to 3 positive nodes.PMID:34690081 | DOI:10.1016/j.clbc.2021.09.004
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Hormonal Therapy | Hormones | Prednisone | Research | Study | Taxotere